ACACS As Modifiers of the IGF Pathway and Methods of Use
Granted: February 26, 2009
Application Number:
20090053239
Human MPTEN genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of MPTEN are provided.
Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3
Granted: February 12, 2009
Application Number:
20090042918
Compounds of formula (I), useful for inhibiting PIM-I and/or PIM-3: and pharmaceutically acceptable salts thereof, wherein Y, Z, R1, R3, Q, X and R4 are as defined above. Pharmaceutical compositions and methods of treating diseases and conditions, such as cancer, are also disclosed.
GALNTS AS MODIFIERS OF THE IGFR PATHWAY AND METHODS OF USE
Granted: January 29, 2009
Application Number:
20090028844
Human MIGFR genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of MIGFR are provided.
ALDOS AS MODIFIERS OF THE IGF PATHWAY AND METHODS OF USE
Granted: January 22, 2009
Application Number:
20090022737
Human ALDO genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of ALDO are provided.
P4HAS AS MODIFIERS OF THE IGFR PATHWAY AND METHODS OF USE
Granted: January 22, 2009
Application Number:
20090025096
Human P4HA genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of P4HA are provided.
PGDS AS MODIFIERS OF THE PTEN PATHWAY AND METHODS OF USE
Granted: January 15, 2009
Application Number:
20090019558
Human PGD genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of PGD are provided.
PDES AS MODIFIERS OF THE IGFR PATHWAYS AND METHODS OF USE
Granted: January 8, 2009
Application Number:
20090013416
Human PDE genes are identified as modulators of the IGFR pathway and thus are therapeutic targets for disorders associated with defective IGFR function Methods for identifying modulators of IGFR comprising screening for agents that modulate the activity of PDE are provided
Kifs as Modifiers of the Rho Pathway and Methods of Use
Granted: January 1, 2009
Application Number:
20090004180
Human KIF23 genes are identified as modulators of the RHO pathway, and thus are therapeutic targets for disorders associated with defective RHO function. Methods for identifying modulators of RHO, comprising screening for agents that modulate the activity of KIF23 are provided.
Mylks as Modifiers of Branching Morphogenesis and Methods of Use
Granted: December 25, 2008
Application Number:
20080317738
Human MYLK genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of MYLK are provided.
Plks as Modifiers of the Beta Catenin Pathway and Methods of Use
Granted: November 6, 2008
Application Number:
20080274122
Human PLK genes are identified as modulators of the beta catenin pathway, and thus are therapeutic targets for disorders associated with defective beta catenin function. Methods for identifying modulators of beta catenin, comprising screening for agents that modulate the activity of PLK are provided.
Pik4ca As Modifier of the Rac Pathway and Methods of Use
Granted: October 23, 2008
Application Number:
20080263684
Human PIK4CA genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of PIK4CA are provided.
Pyrimidine Derivatives As Kinase Modulators and Method of Use
Granted: October 9, 2008
Application Number:
20080249079
The invention provides compounds and methods for inhibition of kinases, more specifically IGF 1 R kinases. The invention also provides compounds and methods for inhibition of wildtype Abl. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal…
SPHKS as modifiers of the p53 pathway and methods of use
Granted: October 2, 2008
Application Number:
20080241131
Human SPHK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SPHK are provided.
Pyrrole Derivatives As Pharmaceutical Agents
Granted: September 25, 2008
Application Number:
20080234270
Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
Eef2k as Modifiers of the Pten/Akt Pathway and Methods of Use
Granted: August 14, 2008
Application Number:
20080193438
Human EEF2K genes are identified as modulators of the PTEN/AKT pathway and thus are therapeutic targets for disorders associated with defective PTEN/AKT function. Methods for identifying modulators of PTEN/AKT comprising screening for agents that modulate the activity of EEF2K are provided.
[1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases
Granted: August 7, 2008
Application Number:
20080188482
The invention provides compounds of formula (I) and methods for inhibition of kinases, more specifically p70S6 kinases, and more preferably p70S6, Akt-1 and Akt-2 kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction…
MARKs as Modifiers of the p53 Pathway and Methods of Use
Granted: July 10, 2008
Application Number:
20080166709
Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.
C-Met Modulators and Methods of Use
Granted: July 3, 2008
Application Number:
20080161305
The present invention provides compounds, which have activity for modulating protein kinase enzymatic activity and are potentially useful for modulating cellular activities such as, e.g., proliferation, differentiation, programmed cell death, migration and chemoinvasion. The present invention also provides compositions containing such compounds, and methods for producing and using such compounds and compositions.
CRBs as Modifiers of Branching Morphogenesis and Methods of Use
Granted: July 3, 2008
Application Number:
20080163386
Human CRB genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of CRB are provided.
Heterocyclic Compounds As Pharmaceutical Agents
Granted: June 5, 2008
Application Number:
20080132519
Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of the disease or disorder directly or indirectly related to the activity of the receptors.
